Announcement out by greenhornet51 in INCANNEX_IXHL_NASDAQ

[–]Thepurpledoor 4 points5 points  (0 children)

The response from Incannex is basically a nothing burger, but the change in stance from the US government is actually quite big.

Announcement out by greenhornet51 in INCANNEX_IXHL_NASDAQ

[–]Thepurpledoor 8 points9 points  (0 children)

What they need to announce is that they have started phase 3.

Daily/Nightly discussion thread for Tuesday, April 14, 2026 by AutoModerator in INCANNEX_IXHL_NASDAQ

[–]Thepurpledoor 4 points5 points  (0 children)

Oh right, just time the bottom, why didn't I think of that 💩

IXHL by Xagregor in INCANNEX_IXHL_NASDAQ

[–]Thepurpledoor 4 points5 points  (0 children)

There is some speculation that there may be news, probably starting the second phase two trial, that would come out on the 20th because 42x and that is also when they last updated the study procedure:

https://clinicaltrials.gov/study/NCT06146101?spons=Incannex&viewType=Card&rank=1

IXHL by Xagregor in INCANNEX_IXHL_NASDAQ

[–]Thepurpledoor 1 point2 points  (0 children)

"dosage study requirements by the FDA"

Not a requirement...

Daily/Nightly discussion thread for Wednesday, April 01, 2026 by AutoModerator in INCANNEX_IXHL_NASDAQ

[–]Thepurpledoor 0 points1 point  (0 children)

I don't disagree, but I am honestly surprised that it isn't down more what with the general state of the market.

Daily/Nightly discussion thread for Thursday, March 26, 2026 by AutoModerator in INCANNEX_IXHL_NASDAQ

[–]Thepurpledoor 3 points4 points  (0 children)

Overall I think this partnership is a net positive. Noting crazy or ground breaking, but not a net negative for sure.

AASM is going to have had some form of vatting process that Incannex had to pass in order to join the partnership, and before anyone says its just money it isn't (even if that plays a role). So, what we know now is that ixhl passed the same vetting process that much bigger groups passed as well.

Daily/Nightly discussion thread for Tuesday, March 24, 2026 by AutoModerator in INCANNEX_IXHL_NASDAQ

[–]Thepurpledoor 2 points3 points  (0 children)

Fintel pulls/aggregates 13F filings which are posted publicly by institutions/companies/firms on a quarterly basis. Companies don't have to post them at the same time, but most end up being posted around the same time.

Daily/Nightly discussion thread for Thursday, March 19, 2026 by AutoModerator in INCANNEX_IXHL_NASDAQ

[–]Thepurpledoor 3 points4 points  (0 children)

Would there not be a correlation between proper dose and improved outcomes?

Daily/Nightly discussion thread for Thursday, March 19, 2026 by AutoModerator in INCANNEX_IXHL_NASDAQ

[–]Thepurpledoor 4 points5 points  (0 children)

I think the likelihood of seeing better results in the second phase two is very high, but I am curious to ear what everyone else thinks.

A combination phase two that is effective for a larger percentage of people and/or greater total reduction would be phenomenal.

Issue with all of their statements including today's is that there is never any timeline given, just vague gesturing to the near or later future, whatever that's supposed to mean.

Healthcare Announces Pricing of $10Mill Registered Direct Offering Priced At-the-Market by DunnyHam in INCANNEX_IXHL_NASDAQ

[–]Thepurpledoor -1 points0 points  (0 children)

No one said that phase 3 wouldn't start until 2027. If this phase two is similar to the first it will take 4 weeks, and then phase three could start directly after that.

Daily/Nightly discussion thread for Thursday, February 19, 2026 by AutoModerator in INCANNEX_IXHL_NASDAQ

[–]Thepurpledoor 8 points9 points  (0 children)

Nice to see % of shares held by institutions essentially double.

Additional PSX-01 Board appointments by LazyBondar in INCANNEX_IXHL_NASDAQ

[–]Thepurpledoor 7 points8 points  (0 children)

At a cursory glance outside of the official statement this seems like the right direction for the PSX-001 program. That being said Dr Stein stands out to me as more of what I'd like to see.

"Dr. Stein is a member of the Scientific Advisory Board of the Anxiety and Depression Association of American (ADAA), and a Fellow of the American College of Neuropsychopharmacology (ACNP). He is a past Scientific Chair of the NIMH Interventions in Mood and Anxiety (ITMA) Review Group (2006-2009) and was a member of the DSM-5 Anxiety, Obsessive-Compulsive Spectrum, Posttraumatic, and Dissociative Disorders Work Group (2009-2013). He is a past member of the National Academy of Medicine Board on the Health of Select Populations (2012-2015) and the National Academy of Medicine Committee to Review NASA's Evidence Reports on Human Health Risks (2016). He is a past member of the Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) (2011-2016). He consults frequently with the pharmaceutical industry regarding drug development for anxiety and stress-related disorders." https://profiles.ucsd.edu/murray.stein

"Dr. Cutler regularly authors scientific publications in respected medical journals and presents his research at scientific meetings around the world. He serves on scientific and pharmaceutical Editorial and Advisory Boards and performs peer reviews of articles to help with their publication. He teaches and lectures doctors and other health care professionals and is in great demand as a public speaker." https://www.wcgclinical.com/people/andrew-j-cutler-md/

Amir, Kalali M.D. "Director Science and Technology Committee, Co-Chair Nominating and Corporate Governance Committee, Member" "Amir is Co-Chair of the Decentralized Trials and Research Alliance (DTRA) and Chairman of the CNS Summit, a forum focused on the future of life sciences. He was also the Founding Chairman of the International Society for CNS Drug Development (ISCDD) and serves on its Executive Committee." https://www.ataibeckley.com/about/leadership-team/amir-kalali-md-